dc.contributor.author | Walson, Judd L | |
dc.contributor.author | Otieno, Phelgona A | |
dc.contributor.author | Mbuchi, Margaret | |
dc.contributor.author | Richardson, Barbra A | |
dc.contributor.author | Lohman-Payne, Barbara | |
dc.contributor.author | Macharia, Steve Wanyee | |
dc.contributor.author | Overbaugh, Julie | |
dc.contributor.author | Berkley, James | |
dc.contributor.author | Sanders, Eduard J | |
dc.contributor.author | Chung, Michael | |
dc.contributor.author | John-Stewart, Grace C | |
dc.date.accessioned | 2013-06-30T12:38:41Z | |
dc.date.available | 2013-06-30T12:38:41Z | |
dc.date.issued | 2008 | |
dc.identifier.citation | AIDS. 2008 August 20; 22(13): 1601–1609. | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637615/ | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/42969 | |
dc.description.abstract | Several co-infections have been shown to impact the progression of HIV-1 infection. We sought to determine if treatment of helminth co-infection in HIV-1 infected adults impacted markers of HIV-1 disease progression.
DESIGN
To date there have been no randomized trials to examine the effects of soil-transmitted helminth eradication on markers of HIV-1 progression.
METHODS
A randomized, double-blind, placebo-controlled trial of albendazole (400mg daily for three days) in antiretroviral-naïve HIV-1 infected adults (CD4 >200 cells/mm3) with soil-transmitted helminth infection was conducted at ten sites in Kenya (Clinical Trials.gov NCT00130910). CD4 and plasma HIV-1 RNA levels at 12 weeks following randomization were compared in the trial arms using linear regression, adjusting for baseline values.
RESULTS
Of 1,551 HIV-1 infected individuals screened for helminth-infection, 299 were helminth-infected. 234 adults were enrolled and underwent randomization and 208 individuals were included in intent-to-treat analyses. Mean CD4 count was 557 cells/mm3 and mean plasma viral load was 4.75 log10 copies/mL at enrolment. Albendazole therapy resulted in significantly higher CD4 counts among individuals with Ascaris lumbricoides infection after 12 weeks of follow up (+109 cells/mm3; 95% CI +38.9 to +179.0, p=0.003) and a trend for 0.54 log10 lower HIV-1 RNA levels (p=0.09). These effects were not seen with treatment of other species of soil-transmitted helminths.
CONCLUSIONS
Treatment of A. lumbricoides with albendazole in HIV-1 co-infected adults resulted in significantly increased CD4 counts during 3-month follow-up. Given the high prevalence of A. lumbricoides infection worldwide, deworming may be an important potential strategy to delay HIV-1 progression. | en |
dc.language.iso | en | en |
dc.subject | HIV-1 progression | en |
dc.subject | Helminth | en |
dc.subject | Co-infection | en |
dc.title | Albendazole treatment of HIV-1 and helminth co-infection: A randomized, double blind, placebo-controlled trial | en |
dc.type | Article | en |
local.publisher | Centre for Clinical Research, Kenya Medical Research Institute, Kenya | en |
local.publisher | Centre for Geographic Medicine Research Coast, Kenya Medical Research Institute, Kenya | en |
local.publisher | University of Nairobi, Department of Pediatrics, Nairobi, Kenya | en |
local.publisher | University of Nairobi, Obstetrics and Gynecology, Nairobi, Kenya | en |
local.publisher | Department of Medicine, University of Washington, Seattle, WA | en |
local.publisher | Department of Biostatistics, University of Washington, Seattle, WA | en |
local.publisher | Department of Epidemiology, University of Washington, Seattle, WA | en |
local.publisher | Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA | en |
local.publisher | Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, UK | en |